Voyager Therapeutics (VYGR) Tops Q3 EPS by 29c

Voyager Therapeutics (NASDAQ: VYGR) reported Q3 EPS of ($0.16), $0.29 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $24.63 million versus the consensus estimate of $11.7 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Chagee Holdings (CHA) Tops Q2 EPS by 3c
• IP Strategy Holdings receives Nasdaq noncompliance notice over late 10-Q